MedTrace Logo

Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma

NCT03114085 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2017-05-15

No results posted yet for this study

Summary

It is an open,randomized,controlled study, and the purpose of this study is to observe and evaluate the efficacy and safety of Apatinib combined with Capecitabine in the treatment of patients with advanced hepatocellular carcinoma.

Conditions

Interventions

DRUG

Capecitabine

Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;

DRUG

Apatinib

Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle

Sponsors & Collaborators

  • First Affiliated Hospital of Guangxi Medical University

    lead OTHER

Principal Investigators

  • Zhiming Zeng, Master · Guangxi Medical University First Affiliated Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-20
Primary Completion
2019-03-20
Completion
2019-05-20

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03114085 on ClinicalTrials.gov